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Abstract
Although non-genomic steroid receptor pathways have been studied over the past decade, little is known about the direct
gene expression changes that take place as a consequence of their activation. Progesterone controls proliferation of rat
endometrial stromal cells during the peri-implantation phase of pregnancy. We showed that picomolar concentration of
progestin R5020 mimics this control in UIII endometrial stromal cells via ERK1-2 and AKT activation mediated by interaction
of Progesterone Receptor (PR) with Estrogen Receptor beta (ERb) and without transcriptional activity of endogenous PR and
ER. Here we identify early downstream targets of cytoplasmic PR signaling and their possible role in endometrial stromal cell
proliferation. Microarray analysis of global gene expression changes in UIII cells treated for 45 min with progestin identified
97 up- and 341 down-regulated genes. The most over-represented molecular functions were transcription factors and
regulatory factors associated with cell proliferation and cell cycle, a large fraction of which were repressors down-regulated
by hormone. Further analysis verified that progestins regulate Ccnd1, JunD, Usf1, Gfi1, Cyr61, and Cdkn1b through PR-
mediated activation of ligand-free ER, ERK1-2 or AKT, in the absence of genomic PR binding. ChIP experiments show that
progestin promoted the interaction of USF1 with the proximal promoter of the Cdc2 gene. Usf1 knockdown abolished Cdc2
progestin-dependent transcriptional regulation and cell proliferation, which also blocked Cdc2 knockdown. We conclude
that progestin-induced proliferation of endometrial stromal cells is mediated by ERK1-2 and AKT dependent early regulation
of USF1, which directly induces Cdc2. To our knowledge, this is the first description of early target genes of progestin-
activated classical PR via crosstalk with protein kinases and independently of hormone receptor binding to the genomic
targets.
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Introduction
Ovarian steroids are considered to act mainly through direct
regulation of transcription via interaction of their receptors with
target genes [1], but rapid effects of steroids independent of
transcriptional responses have been reported in different tissues
and cellular types [2–4]. Steroid hormones are able to rapidly and
transiently activate the SRC/RAS/ERK kinases cascade through
a direct interaction between cytoplasmic steroid receptors with
SRC [3,5–6]. This activation is essential for some physiologic
responses to hormones, such as cell proliferation or inhibition of
apoptosis [7]. Moreover, estrogen receptor alpha (ERa) also
interacts with the regulatory subunit of the phosphoinositol-3-
kinase, leading to the ER activation as well as the activation of
AKT [8]. Activation of cytoplasmic cascades could be involved in
the transcriptional regulation of some ovarian hormone target
genes. RSK2 kinase, which interacts with the hormone binding
domain of ERa and phosphorylates it at Ser 167 [9], can also
phosphorylate histone H3 at S10 and thus participate in gene
activation. A direct connection between rapid kinase activation
and gene induction by steroid hormones has been reported in
breast cancer cells. The activation of ERK and MSK1 and their
recruitment, along with phosphorylated PR (pPR) to the MMTV
promoter leads to phosphorylation of histone H3 at S10,
displacement of HP1g, and recruitment of ATP-dependent
remodeling complexes, coactivators, and RNA polymerase II
[10]. These results show that the cytoplasmic and nuclear
pathways activated by steroid hormones converge on chromatin
to enable gene regulation in T47D cells.
The uterine endometrium undergoes cyclic stages of prolifer-
ation, differentiation and remodelling under the control of steroid
hormones. Even though proliferation of endometrial stromal cells
followed by differentiation into decidual cells is dependent on
progesterone and estradiol [11,12], a dominant role of progester-
one during decidualization has been demonstrated using anti-
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progestins [13,14]. Progesterone alone is able to induce uterine
stromal proliferation before decidualization, an effect potentiated
by estrogens [15]. Evidence that progesterone receptor (PR) is
crucial for decidualization comes from PR-deficient mice [16].
Our previous studies in the UIII stromal cell line derived from rat
endometrium concluded that induction of proliferation upon the
addition of progestins requires both progesterone and estrogen
receptor beta (ERb) [17]. The interaction of both receptors in the
cytoplasm is needed to activate the extracellular signal-regulated
kinases 1 and 2 (ERK1-2) as well as the AKT signaling pathway.
UIII cells do not express ERalpha but express PR and ERbeta
though at levels insufficient for hormonal transactivation of their
respective target genes via binding to genomic target sequences
[17]. However, whether the progestin action via kinase signaling
can regulate genes independently of PR binding to chromatin
remains an open question. In this study we used UIII cell line to
explore the cohort of early regulated genes by the cytoplasmic
component of progesterone-PR pathway independent of PR
binding to genomic targets. We describe early downstream targets
of progestin-dependent ERK and AKT activation via PR and ER,




Available at SI M&M.
Cell Culture and Hormone Treatment Experiments
UIII rat normal uterine stromal cells were kindly provided by
Dr. Cohen and maintained in M199 medium supplemented with
10% fetal bovine serum (FBS) and gentamycin (100 mg/ml) at
37uC in humidified 95% air with 5% CO as the authors first
described them [18]. Culture media were changed every 2 days.
For hormone treatment experiments in absence of serum, cells
were cultured in FBS and, 48 h later, media were replaced by
fresh M199 without serum. After three days in serum-free
conditions, media were replaced by either vehicle or hormones.
RNA Extraction, sqPCR and qPCR Analysis
In all cases total RNA isolation and cDNA synthesis were
performed as described [17].
SqPCR and qPCR: JunD, Usf1, Cyr61, Pten, Cdkn1b, Crebbp, Gfi1
and b-actin mRNA levels were quantified as described [19]. The
primers used are detailed in Table S1. Find details of these
protocols in SI M&M.
Microarray Analysis
Serum starved UIII cells were treated with ethanol or R5020
10210 M during 45 minutes. Isolated RNA was hybridized to an
oligo microarray (60 mer) from Agilent (G4130). cDNA was
synthesized according to manufacturer’s instructions (Agilent).
Detailed protocols are available at www.agilent.com/chem/
dnamanuals-protocols. Briefly, the cDNA was used as a template
for synthesis, amplification and staining of cRNA. The dCTP
conjugated to cy3 or conjugated to cy5 was incorporated by T7
RNA polymerase to obtain cRNA-cy3 or cRNA-cy5 from the
cDNA vehicle or progestin treated cells respectively. The first
experiment was performed with an inverted dye swap staining
(indicated as DS in figure legend). The cRNA-cy3 and cRNA-cy5
were purified before chip hybridization. The images of competitive
resulting hybridization were scanned and data from images were
extracted to quantify gene expression on each spot. The data
analysis was performed with AFM 4.0 [20]. Microarray analysis
was performed at the Microarray unit from the Centre de
Regulacio´ Geno`mica, Barcelona, Spain. The dataset was reported
to GEO databank under GSE55992 accession number.
Statistical Analysis for Microarrays Data
The details of experimental design, transformation and statis-
tical treatment of microarray data protocols are available at SI
M&M.
In Silico Analysis
In silico analysis was performed using GO Tree Machine and
OntoExpress softwares. Details of the analysis in SI M&M.
The DNA sequence corresponding to the PR binding site in
Cdc2 promoter from T47D human mammary ephitelial cells
genome was extracted from ENCODE [21] and a nucleotide
alignment was performed with NCBI/ BLAST/ blastn suite.
siRNA and Transfection
For knockdown with siRNA and hormone treatment experi-
ments in absence of serum, UIII cells were cultured in FBS and, 24
hs later, media were replaced by white M199 with 10% dextran-
coated charcoal- foetal bovine serum (DCC-FBS) and without
antibiotics, in this conditions the cells were transfected. CDC2
siRNA (sc-29253, Santa Cruz Biotechnologies, California, USA),
USF1 siRNA (sc-270501, Santa Cruz Biotechnologies, California,
USA) or scramble siRNA (Negative control siRNA, Quiagen,
Gene Glove) were used in 100 nM. Lipo 2000 (Lipofectamin
2000, Invitrogen) was used as the vehicle of transfection. Forty-
eight hours later media were replaced by fresh M199 without
serum and the cells were starved overnight. After one night in
serum-free conditions, media were replaced by either vehicle or
hormones.
Western Blots
Protein samples were analyzed as described [17]. Quantification
of blot intensities were performed with data obtained within a
linear range of exposure (G:Box-Syngene). Details of these
protocols in SI M&M.
Chromatin Immunoprecipitation Experiments
ChIP experiments were performed as described [22]. UIII cells
were seeded in 145 mm culture dishes and after hormonal
treatments, chromatin was collected. The antibodies used for the
immunoprecipitations were USF1 (Santa Cruz Bio. H-86), PR
(Santa Cruz Bio. H-190) and normal rabbit IgG (Cell Signaling).
The primers used for qPCR performed on immunoprecipitated
(IP) and non-immunoprecipitated (input) DNA are detailed in
Table S1 and S2. USF1 enrichment was expressed as percentage
of input relative to T0 according to Comparative Ct method. Ct
values were acquired with Bio Rad CFX Manager. PR
enrichment was detailed in Figure 5C.
Statistical Analysis
Analysis of variance followed by Tukey Multiple Comparison
Test was used for statistical testing in all figures unless otherwise
indicated. t-Test was performed to compare mRNA expression
Fig. 2B and Fig. 5E, and cell number in Fig. 4E and Fig. 5F.
Differences were considered significant if P,0.05. Statistical
analysis was carried out with GraphPad Prim 4.0 (GraphPad
Software Inc., La Jolla, CA, USA).
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Results
R5020 Modulates Early Genes Expression in Stromal
Endometrial UIII Cells
We initiated the search for early downstream targets of the
R5020 signaling pathway by exploring the optimal concentration
and time point for gene expression profiling. Cyclin D1 (Ccnd1)
was used as a well-known cell cycle regulator involved in
progestin-dependent proliferation [23–24]. Two progestin con-
centrations were used: 10210 M, known to activate the cytoplasmic
initiated effects in UIII [17], and 1028 M, usually associated to
steroid transcriptional activation. Both concentrations transiently
induced Ccnd1 mRNA levels with a maximum at 45 minutes, but
the lower concentration was more effective (Fig. 1A). When a
larger range of R5020 concentrations was tested at 45 minutes, the
optimal concentration was 10210 to 1029 M (Fig. 1B shows the
statistical quantification of 3 experiments). Pre-treatment of the
cells with the PR antagonist RU486 abolished the Ccnd1 mRNA
induction (Fig. 1C), indicating that it is mediated by the classical
PR. The ER antagonist ICI 182780 had a similar effect revealing
that Ccnd1 regulation by R5020 requires ligand-free ER (Fig. 1C).
Pre-treatment with PD 098.059 alone increased Ccnd1 transcript
levels (Fig. 1C) and diminished the increase in transcript levels
induced by R5020, indicating that activation of ERK1-2 plays a
complex role in controlling basal and hormone regulated Ccnd1
expression. Instead, PI-3K/AKT inhibitor LY 294.002 (LY)
blocked progestin induction of Ccnd1, suggesting that activated
AKT is involved in Ccnd1 progestin-dependent regulation (Fig. 1C).
Another progesterone target gene c-Myc was also induced by 10210
M R5020 in these conditions (Fig. 1D). Cdkn1a/p21 mRNA was
only slightly induced in early response to 10210 M R5020 (Fig. 1D),
but this gene is known to be regulated at later time points after
progestin treatment [25].
Transcription Factors and Cell Cycle Regulators are the
Main Functional Categories of the Progestin-dependent
Gene Network in Endometrial Stromal Cells
RNA analysis with oligonucleotide micro-arrays (Agilent 44 K
arrays) from cells cultured for 45 minutes with vehicle or 10210 M
R5020 showed that 97 genes are significantly up-regulated (over
1.40-fold, B Rank $85B), and 341 genes are significantly down-
regulated (more than 21.40 fold; B Rank $85B) (Tables S3 and
S4, respectively; the fold change (FC) numbers represent the
average from three biological replicates and a dye swap data set).
GOTM software (Gene Ontology Tree Machine) [26] analysis
of the 438 progestin-regulated genes showed that the most
significant differentially over-represented ontology terms were
related mainly to transcription regulation: Cellular Component
Categories, nucleus (44 genes, with P = 0.001) and chromatin
(5 genes with P = 0.004); Functional Component Categories,
transcription factor activity (18 genes, 5 of which were up-
regulated, JunD, Mafk, Klf4, Usf1, Crebbp, and 13 were down-
regulated RGD1308861, Egr3, Nfix, Ches1, Runx3, E2f1, Tcf3,
Caskin1, Klf1, Gfi1, Tcfdp2, Arid4a, Mllt10, with P = 0.002) (Fig. 2B,
TF), chromosome organization and biogenesis (8 genes, 3
of which were up-regulated, Rbbp4, Crebbp, Pdcd8, and the
remaining 5 were down-regulated, Smarcc1, Setdb1, Tnks1bp1,
Tcf3, Klf1, with P = 0.006), ubiquitination-dependent protein
catabolism (2 up-regulated genes, Ube3a, Ube2n, and 3 down-
regulated genes, Ate1, Arih2, Usp7, with P = 0.006), and central
nervous system development (2 up-regulated genes, Klf4,
Ube3a, and 7 down-regulated genes, B3gnt5, Odz2, Pitx3, E2f1, Atrx,
Sept4, Pitpnm1, with P = 0.007) (Fig. 2A).
The search for the ontology terms Cellular Proliferation and
Cell Cycle yielded 23 genes (Fig. 2B, CCR-Cell Cycle Regulators).
Seven of them are transcription factors (Crebbp, Ches1, Runx3 E2f1,
Tcf3, Gfi1 and Tcfd2) and 3 are chromatin modifiers (Rbbp4, Tcf3
and Crebbp). Eight genes were up-regulated and 15 were down-
Figure 1. Low concentration of progestin increases Ccnd1
transcript levels in UIII endometrial stromal cells. A) UIII cells
were treated with vehicle (–), 10210 M R5020 (210) or 1028 M R5020 (2
8) during 30, 45 and 60 minutes in serum-free culture medium and total
RNA was isolated and subjected to sq-PCR. Figure shows sybr green-
stained gels of sq-PCR products for Ccnd1 and b-Actin of a
representative experiment selected from three independent experi-
ments with similar results. B) UIII cells were treated with vehicle (0) or
with increasing 10211 M (–11) to 1028 M (–8) concentrations of R5020
(R5020 (logM)) for 45 minutes. The graph represents the values for
Ccnd1 fold change relative to b-Actin were divided by the vehicle-
treated value (control). Data represent average 6 SEM from 5 to 9
independent experiments. **P,0.01, ***P,0.001 v. vehicle. C) Anti-
progestin RU486, antiestrogen ICI and inhibitors of ERK1-2 and AKT
pathways effects on Ccnd1 mRNA expression. Cells were pre-treated for
30 minutes with 10–8M RU486 (RU), 10–7 M ICI 182.780 (ICI), 50 mM PD
98.059 (PD) or 50 mM LY 294.002 (LY) followed by a 45 minute
treatment with vehicle (–) or 10210 M R5020 (+) as indicated. Figure
shows sybr green-stained gels of sq-PCR products for Ccnd1 and b-Actin
of a representative experiment selected from three independent
experiments with similar results. D) Ccnd1, c-Myc and Cdkn1a/p21
transcript expression was analysed in UIII cells treated as described in B.
doi:10.1371/journal.pone.0097311.g001
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regulated, of which 7 were inhibitory functions (Fig. 2B). Ches1,
Tcf3, Ccnc and Gfi1 are transcriptional repressors, Pten and Runx3
are tumor suppressors, and Cdkn1b is a cell cycle inhibitor. These
findings suggest that the progestin-dependent proliferation could
be partly achieved via inhibition of repressors and partly via
regulation of immediate early genes associated to the transcrip-
tional control of cell cycle regulatory molecules.
The Pathway Express Onto-Tool [27] identified seven genes
(Cacng2, Jund, Mras, Pdgfrb, Pla2g2c, Ppp3r1 Sos1) encompassed in
the MAPK (Mitogen-activated protein kinases) signaling pathway,
confirming the significance of MAPK signalling in the early
response to progestin in UIII cells (Fig. 2C).
The expression of transcription factors and cell cycle regulators
found by microarrays was validated using q-PCR. The mean fold
changes obtained by microarrays and q-PCR are shown in Fig. 2D
and 2E respectively, and confirm the validity of the microarray
data. The results of sq-PCRs stained with sybr green are shown as
well (Fig. 2F).
Role of Hormone Receptors and Kinases on Progestin
Gene Regulation
We used hormone receptor antagonists and kinase specific
inhibitors to study the involvement of PR (RU), ER (ICI), ERK1-2
(PD) and AKT (LY) on progestin regulation of the validated target
genes including JunD, Usf1, Crebbp, Gfi1, Cyr61, Pten and Cdkn1b.
Figure 3 shows the values of changes in gene expression of the
tested genes in cells treated with 10210 M R5020 for 45 min after
preincubation for 30 min with vehicle or with RU486, ICI182780,
PD98059 and LY294002. PR antagonist RU486 blocked up-
regulation of JunD, Cyr61 and Usf1 (Fig. 3A and 3C), as well as
down-regulation of Gfi1 and Cdkn1b (Fig. 3B and 3C). In absence
of progestin, the antagonist treatment down-regulated Gfi1
transcript expression, indicating that basal Gfi1 transcription
requires ligand-free PR (Fig. 3B). These results show that progestin
regulates JunD, Cyr61, Usf1, Gfi1 and Cdkn1b through classic PR.
ER antagonist ICI 182780 revealed that Usf1, Gfi1, Cyr61, and
Cdkn1b regulation by R5020 requires ligand-free ER (Fig. 3A, 3B
and 3C). JunD mRNA expression level in the presence of ICI alone
was similar to its expression in the presence of ICI+R5020 and
higher than in control conditions (Fig. 3A). However, the level of
JunD mRNA in presence of both R5020 and ICI was lower than
with R5020 alone. Additionally, ICI treatment compromised the
response of JunD and Cdkn1b genes to R5020 due to a differential
effect on the basal activity of the two genes: whereas it increased
basal activity of JunD, it decreased basal activity of Cdkn1B. We
conclude that, in addition to PR, ER is partially involved in the
induction of JunD by progestin (Fig. 3A). Pre-treatment with ICI
blocks the progestin down-regulation of Gfi1 and Cdkn1b,
Figure 2. Transcription Factors and Cell Cycle Regulators are
the main early progestin-regulated genes. A) The categories of
over-represented Gene Ontology terms (GO terms) are shown by their
decreasing p-values. The categories were identified by GOTM (Gene
Ontology Tree Machine) software over the statistical regulated genes as
indicated in supplementary Materials and Methods. Up-regulated genes
percentages are shown in red, and down-regulated percentages are
shown in green. B) Venn diagram shows the set of TF and CCR
regulated by progestin. A GOTM search of cellular proliferation and cell
cycle GO terms identified 23 genes, named cell cycle regulators (CCR) in
the Figure. Seven of them were also categorized as transcription factors
(TF) present in A. Up-regulated genes are shown in red, and down-
regulated are shown in green. C) The signaling pathways associated to
the differential gene expression pattern are shown by their decreasing
p-value. Pathways identified by Pathway Express Software containing at
least four progestin-dependent regulated genes included in a given
Signalling Pathway (SP), with a p-value#0.05. The percentage of up-
regulated genes within a given signalling pathway is shown in red, and
down-regulated genes are shown in green. Statistical details are
described in M&M. D) The table shows individual fold changes of three
independent biological samples (1,2,3) and one dye swap data set (1DS)
analyzed by microarray, and the mean fold change of all 4 values
(Media). Fold changes over vehicle treated cell values were calculated as
described in SI M&M. E) q- real time PCR validation for JunD, Usf1,
Crebbp, Gfi1, Cyr61, Pten and Cdkn1b mRNA relative to b-Actin. The
figure shows media 6 SEM from three to six independent experiments.
*P,0.05, **P,0.01, ***P,0.001 v. vehicle treated cells. F) sq-PCR
validation for transcription factors (TF) JunD, Usf1, transcription factors
and cell cycle regulators (TF+CCR) Crebbp, Gfi1, Cyr61, and cell cycle
regulators (CCR) Pten, Cdkn1b and b-Actin.
doi:10.1371/journal.pone.0097311.g002
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suggesting that the ligand-free ER is required for progestin gene
repression.
Pre-treatment with PD 098.059 abolished R5020 induction of
JunD, Usf1, and Cyr61 (Fig. 3A and 3C), as well as down-regulation
of Gfi1 and Cdkn1b (Fig. 3B and 3C).
PI-3K/AKT inhibitor LY 294.002 (LY) precludes progestin
induction of JunD, Usf1 and Cyr61 as well as repression of Gfi1 and
Cdkn1b (Fig. 3A, 3B and 3C). In the presence of LY, R5020
reduced Pten mRNA levels to a lower extent than in its absence.
Although the statistical significance of this finding remains to be
established, the data suggest that progestin-dependent inhibition of
Pten transcript expression requires ERK1-2 activation and is
independent of AKT activation.
Although individual genes show more complex behaviours, such
as Gfi1 in response to RU and Cdkn1b in response to ICI, the
inhibitory effects of RU, ICI, PD and LY suggest that regulation
by progestin R5020 of these genes needs classical PR, ER, ERK1-
2 and/or AKT activation. Thus at least two different signaling
pathways are involved in the short-time progestin control of the
expression of these transcription factors and cell cycle regulators.
Since the effects of ICI indicate a signaling pathway that
involves ER activation in the absence of estrogens, we have tested
the effect of estrogens on the expression of validated R5020-
regulated genes. Except in the case of Gfi1 repression, estradiol
(1028 M) did not show the same regulation pattern as observed
with R5020 (Fig. S1), suggesting that the outcome of activation of
the PR-ERbeta pathway does not depend on estradiol as a ligand.
In summary, these results show that progestin-dependent
regulation is a consequence of ERK1-2 and/or AKT activation
that requires ligand-free ER. Thus at least two different kinase
signaling pathways are involved in the short-time progestin control
of the expression of these transcription factors and cell cycle
regulators.
Downstream Targets of Progestin-regulated
Transcription Factors Usf1 and Crebbp
We next investigated the involvement of downstream target
genes of regulated transcription factors in progestin-dependent
proliferation. Cdc2 and cyclin b1 (Ccnb1) have been described as
USF1 target genes [28–29], while p21 (Cdkn1a) and c-Myc are
Figure 3. PR, ER, ERK1-2 and AKT activation on progestin-regulated transcription factors and cell cycle regulators mRNAs. UIII cells
were pre-treated for 30 minutes with 1028 M RU486 (RU), 1027 M ICI 182.780 (ICI), 50 mM PD 98.059 (PD) or 50 mM LY 294.002 (LY) followed by a
45 minute treatment with vehicle (–) or 10210 M R5020 (+) when indicated. A) q-PCR of mRNAs from JunD and Usf1 relative to b-Actin mRNA. B) q-
PCR of Crebbp and Gfi1 mRNA relative to b-Actin mRNA. C) q-PCR of Cyr61, Cdkn1b and Pten mRNA relative to b-Actin mRNA. The figures show media
6 SEM from three independent experiments. *P,0.05, **P,0.01, ***P,0.001 vs vehicle treated cells.
doi:10.1371/journal.pone.0097311.g003
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regulated by GFI1[30], and Cdc6 and cyclin E (CcnE) are targets of
CREBBP [31].
Time-course experiments of response to R5020 showed that the
levels of mRNA for Usf1 increased at 45 min, decreased slightly at
2 and 6 hours and reached a maximum at 12 hours (Fig. 4A). This
pattern gathers strength for the Cdc2 mRNA levels that were up-
regulated at 45 min, returned to control levels at 2 and 6 hours,
and increased again at 12–24 hours (Fig. 4A). Ccnb1 mRNA was
also transiently up-regulated at 45 min and at 12 hours (Fig. 4A).
These effects are all mediated by PR as they were blocked by the
antiprogestin RU486 at 12 hours treatment (Fig. 4B).
Through western blot, we analyzed the protein levels of USF1,
its target CDC2/CDK1, the S-phase marker PCNA, and total
ERK2 in cells treated with vehicle or 10210 M R5020 during 6, 12
and 24 hours (Fig. 4C). USF1 and CDC2 were increased at 6 and
24 hours, and showed basal levels at 12 hours (Fig. 4C). On the
other hand, PCNA increased only at 12 hours, suggesting that
DNA synthesis occurs as a consequence of the initial rise in USF1
and in its target CDC2 at 6 hours (Fig. 4C).
In addition to USF1 targets, we also looked at CREBBP target
CcnE. Although significant Crebbp mRNA induction by progestin
was not consistently observed, the mRNA levels of CcnE, a target
gene of CREBBP (Fig. S2A), increased gradually from 45 min to
12 hours in response to progestin treatment. CcnE progestin
dependent induction after a 12 hours treatment was abolished by
Figure 4. CDC2, a USF1 target, is responsible for progestin-induced UIII cell growth. A) UIII cells were treated at 45 minutes, 2, 6, 12 and
24 h with 10210 M R5020 as indicated in Fig. 1A. The values for mRNAs fold change of Usf1, Cdc2, Ccnb1 relative to b-Actin were divided by the
vehicle-treated value for each time point tested. Data represent average 6 SEM from 3 to 5 independent experiments. *P,0.05, **P,0.01, ***P,
0.001 v. vehicle. B) shows representative products of sq-PCR of these genes in 30 minutes RU486 pre-treated cells from three independent
experiments with similar results. C) shows USF1, CDC2 and PCNA protein expression in which fold change relative to ERK2 was divided by the vehicle-
treated value at 6, 12 and 24 h progestin treatment. Data represent average6 SEM from 3 independent experiments. *P,0.05, **P,0.01, ***P,0.001
v. vehicle. D) Number of cells after 24 and 72 h of vehicle (2) and 10210 M progestin treatments in UIII cells were treated as indicated in Fig. 1B.
***P,0.001. E) Number of cells transfected without siRNA, with scramble siRNA and with Cdc2 siRNA 24 h before treatment with vehicle and
progestin. ***P,0.001. Lines in both figures indicate statistical comparison; standard deviation is indicated. Inset E) Western blots for CDC2 and
GAPDH of cell transfected with Cdc2 and scramble siRNAs.
doi:10.1371/journal.pone.0097311.g004
PR-Kinase Mediated Endometrial Targets
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RU486 pretreatment (Fig. S2B), indicating the need for the classic
PR.
USF1-induced CDC2 is Required for Progestin-dependent
Proliferation
After 24 hours of progestin treatment, the cell number increased
2 fold (Fig. 4D). A 60 percent depletion of CDC2 with specific
siRNA (Fig. 4E insert) precluded progestin dependent cell
proliferation while cell proliferation was maintained in cells
transfected with scramble siRNA (Fig. 4E), demonstrating that
CDC2 mediates progestin-dependent proliferation.
To explore the mechanism of USF1 transcription factor
regulation of Cdc2 expression, we performed ChIPs experiments
over a region of Cdc2 promoter (see Cdc2 promoter pattern at
Figure 5A), which contains two specific nucleotide heptamers
known to function as binding sites for USFs and to be highly
conserved in different species [28]. This ChIP showed that after
30 min of treatment with R5020 USF1 binds to both Cdc2
promoter sequences (Figure 5B, regions 1 and 3) while two other
nearby regions were negative for USF1 binding (Figure 5B,
regions 2 and 4). These results are consistent with binding of USF1
to its target Cdc2 mediating the regulated expression of this cell
cycle kinase in UIII cells.
We have shown that endogenous PR is not able to induce
transcription of an exogenous PRE construction in UIII cells [17].
Therefore, we did not expect to find PR binding to DNA target
sequences. Nevertheless, to exclude PR direct interaction with
Cdc2 promoter, prior to hormone treatment (T0) and 60 min after
addition of 10210 M R5020 (R60), we tested PR binding to Cdc2
proximal promoter, 20.75 Kb to +0.5 Kb relative to the
transcription start site (TSS) using 3 of the USF1 ChIP pairs of
primers (regions 2, 3 and 4 in Fig. 5B) and an extra pair which
partially overlaps with region 1 (region 1 bis in Figure 5C). The
results confirmed the absence of PR binding to Cdc2 DNA
proximal promoter sequence (Fig. 5C) although we do not exclude
binding to other distant regions of the gene. PR is recruited on a
distal position (210.9 Kb to 210.7 Kb) of Cdc2 promoter in
T47D human mammary ephitelial cells under progestin treatment
[21] and this region contain several potential PREs (TGTYCY),
but this region is not conserved in mouse or rat genomes (NCBI/
BLAST/ blastn suite).
To compare Cdc2 regulation by USF1 and PR, we analyzed
USF1 recruitment in ENCODE human cell lines (http://genome.
ucsc.edu/) [32] and PR recruitment in human Ishikawa endome-
trial cells (La Greca A et al., unpublished data) and T47D cells
[21]. The USF1 element in Cdc2 described in A549 epithelial cell
line derived from a lung carcinoma tissue-, H1-hESC embryonic
stem cells and HepG2 hepatocellular carcinoma was in the region
+1044 to +1300 from the TSS, differently positioned from what
we found for USF1 recruitment (Fig. 5D). PR recruitment in Cdc2
of human Ishikawa endometrial cells was negative (La Greca et al.,
unpublished data), while it was positive in T47D cells [21], hinting
at possible tissue specificity.
Progestin-dependent regulation of Cdc2 is evident from the fact
that after 12 hours of progestin treatment, the Cdc2 transcript
expression increased around four times over vehicle treated cells
(Fig. 4A). To confirm that progestin regulation of Cdc2 was
mediated by USF1, we knocked down USF1 and measured Cdc2
mRNA after 12 hours of progestin and vehicle treatment. A 60
percent depletion of USF1 with specific siRNA (see Western blot
in Fig. 5E insert) abolished progestin-dependent Cdc2 transcript
upregulation, while Cdc2 mRNA expression was not modified in
cells transfected with scramble siRNA (Fig. 5E). This finding
demonstrates that Cdc2 direct transcriptional regulation is medi-
ated by progestin-dependent USF1. Also, USF1 specific siRNA
abrogated progestin-dependent proliferation (Fig. 5F). Taken
together, these results point to Cdc2 as a possible cell cycle target
of early transcription factor USF1 whose expression is selectively
induced by progestin via the interaction of PR-ERbeta and ERK
and AKT activation independently of PR binding to genomic
targets (Fig. 5G).
Discussion
In this study we explored the possibility that steroid hormones
can regulate gene expression via activation of kinase signalling
pathways without requiring a direct interaction of their receptors
with the target genes in chromatin. As we have shown previously,
UIII cells are a good model system to study¨cytoplasmic initiated
effects’’ of low concentration of progestin in the presence of PR
and ERb but not ERa and without transcriptional activity of both
endogenous receptors [17]. Here we identify transcription factors
as downstream molecular targets of progestin activation of ERK1-
2 and AKT involved in proliferation of UIII cells and specifically
explore CDC2 –a USF1 transcription factor target- involved in
proliferation.
We first analyzed the expression of cyclinD1, the regulatory
component of the complex CyclinD1-CDK4 that, together with
cyclinE-CDK2, promotes S phase entry through the phosphorila-
tion of pRb [33]. Even though there are no progesterone response
elements (PRE) on Ccnd1, progestin regulates its transcription
through a proximal promoter c-Ets-2 binding site [34–35]. We
found a rapid and transient induction of Ccnd1 transcripts in
progestin treated UIII cells mediated by classical PR. Unexpect-
edly, optimal transcriptional activation was observed in response
to low progestin concentrations, 10210 M and 1029 M R5020.
This observation is consistent with our previous results showing
that the optimal concentration of progestin inducing UIII cell
proliferation as well as ERK1-2 and Akt activation is in the
subnanomolar range, and suggests that Ccnd1 is a mediator of the
proliferative response. Therefore we used a low concentration of
progestin (R5020 10210 M) and a short time treatment (45 min-
utes) to identify the global set of early target genes involved in the
initiation of progestin-dependent proliferation in endometrial cells.
Using oligonucleotide microarrays, we identified 438 regulated
genes, of which 78 percent were significantly down-regulated,
suggesting that repression could be a relevant molecular mecha-
nism by which progesterone regulates stromal proliferation in
endometrium. The over-represented ontology terms revealed that
progestin downstream genes are mainly involved in the regulation
of transcription, notably transcription factors, steroid receptor co-
regulators and chromatin remodelling molecules/regulators/
modifiers/. We detected a set of 23 genes encompassed in the
Cellular Proliferation and Cell Cycle ontology terms and found
that 9 of them were also present in the overrepresented set of
transcription factors and chromatin remodelling genes. We
validated the expression of genes described as transcription factors
(JunD, Usf1), as transcription factors and cell cycle regulators
(Crebbp and Gfi1), and as cell cycle regulators (Cyr61, Pten and
Cdkn1b).
Usf1 (up-regulated 1.42-fold) encodes a ubiquitous transcription
factor that regulates gene networks involved in stress and immune
response, cell cycle and cell proliferation. USF transcription factors
have been shown to be targets of ERK1-2 in epidermal
keratinocytes [36]. USF1 controls cell proliferation by targeting
cell cycle genes such as p53 [37], Cdc2 [28] and cyclin b1 [29].
CDC2 or cyclin dependent kinase1 (CDK1) forms a complex with
CyclinB1, whose activation by phosphorylation promotes the entry
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Figure 5. Progestin directs USF1 binding to Cdc2 promoter. A) Cdc2 proximal promoter (–0.75 Kb to +0.5 Kb) contains two specific heptamers
binding sites for USFs and two nearby unrelated regions. B) USF1 is recruited to the Cdc2 proximal promoter sequence. UIII cells were treated with
10–10 M R5020 for 30 min and subjected to ChIP with IgG as control, or a USF1 antibody and the purified DNA was used for q-PCR. The values
represent average 6b SEM fold changes relative to inputs over T0 from 3 independent experiments for each of the four regions (1–4) shown in the
upper Cdc2 promoter scheme. *P,0.05, **P,0.01 v. vehicle. C) PR is not recruited to the Cdc2 proximal promoter sequence. After performing PR ChIP
in untreated (2) and R5020 treated cells (R), we analyzed the recruitment to Cdc2 proximal promoter sequence by qPCR using 4 pairs of primers, 3 of
which were used for USF1 ChIP analysis (Regions 2, 3, and 4) and a pair (1 bis), which covers the corresponding region (Figure 5C). Ct: Crossing
threshold, N/D: not detected. D) USF1, PR and phospho Pol II recruitment to Cdc2 promoter (210 Kb to +1 Kb) in UIII rat endometrial cells, in human
cell lines (ENCODE: A549 epithelial cell line derived from a lung carcinoma tissue, H1-hESC embryonic stem cells, HepG2 hepatocellular carcinoma),
Ishikawa human endometrial cells [La Greca et al, unpublished data], and T47D epithelial mammary cells [30]. E) USF1 mediates progestin regulation
of Cdc2. The graph shows Cdc2 mRNA expression determined by q-PCR after 12 h of treatment with vehicle and progestin of cells transfected with
scramble siRNA and with Usf1 siRNA 48 h before. ***P,0.001, NS: Non Significant. Lines indicate statistical comparison; standard deviation is
indicated. Inset E) Picture shows western blots for USF1 and GAPDH of cells transfected with Usf1 and scramble siRNAs. F) Number of cells
transfected without siRNA, with scramble siRNA and with Usf1 siRNA 24 h before treatment with vehicle and progestin. **P,0.01, ***P,0.001, NS:
not significant. Lines indicate statistical comparison; standard deviation is indicated. G) Model depicting PR-ER, ERK and AKT activation necessary for
PR-Kinase Mediated Endometrial Targets
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in the mitotic phase of the cell cycle [38]. USF1 specifically
mediates transcriptional activation of Ccnb1 (Cyclin B1) just before
and during mitosis in HeLa cells [29].
We found that Usf1 and its targets Cdc2 and Ccnb1 were
transiently induced at 45 min and at a later time (12 hours). USF1
and CDC2 proteins also showed progestin-dependent regulation.
CDC2 hormone-dependent regulation preceded PCNA increase,
supporting recent evidence that CDC2 regulates G1 progress and
G1-S phase transition [39]. It is to be noted that the reduction of
CDC2 by means of siRNA UIII cells did not respond to progestin
effects.
To test USF1 regulation of Cdc2 at a transcriptional level we
performed ChIP and tested USF1 recruitment over Cdc2 proximal
promoter. Our results show a USF1 progestin-dependent recruit-
ment to two specific heptamers in Cdc2 promoter region, which
were described as USF binding sites [28]. The genomic position of
these bindings was different from the one described for several
human cell lines in ENCONDE project (http://genome.ucsc.edu/
). We confirmed the absence of PR binding to Cdc2 DNA proximal
promoter sequence in accordance with the absence of PR binding
in Chip seq experiments performed in Ishikawa cells treated with
R5020 (data not shown) and in T47D cells treated with R5020
[21]. This encourages the study of Cdc2 gene expression regulation
mediated by cytoplasmic PR pathway. A functional approach
using siRNA showed that depletion of USF1 abolished Cdc2
progestin-dependent transcriptional regulation and progestin-
dependet proliferation, confirming that USF1 mediates the
progestin transcriptional regulation of Cdc2 and R5020 induced
proliferation.
To explore the repertoire of the described transcription factors
binding sites to the complete set of TF regulated by R5020 we
performed an in silico search using TRANSFAC software (www.
gene-regulation.com) over the set of 32 progestin regulated genes
shown in Fig. 2D. This analysis resulted in the absence of PR
elements (PRE), and in the presence of steroid hormone response
elements (SHRE) in 3 genes, of USF1 elements in 15 genes, of
ELK1 elements in 14 genes and of other non-SHRE in the
remaining 13 genes. This pattern is consistent with non-direct
binding of PR to this set of kinase regulated genes.
Our finding suggests that the progestin regulated interaction
between USF1 and its target Cdc2 could regulate the expression of
this cell cycle kinase in UIII cells in the absence of genomic PR
binding.
Our present results identify for the first time in endometrial
stromal cells a set of early target genes of progestin-activated
classical PR via ERb and protein kinases. Progestin regulation of
JunD, Usf1, Gfi, Pten, Cdkn1b and Cyr61 required ERK1-2 or AKT
activation and ligand-free ERb, while regulation of Ccnd1 was
mediated by activation of AKT but not ERK1-2. This study
suggests that the downstream targets of cytoplasmic kinases
activated by PR in UIII cells are predominantly early induced
transcription factors and repressors or inhibitors of cell prolifer-
ation that are down-regulated by progestins, as well as activators of
cell cycle regulators. One of them, CDC2, is up-regulated by
USF1 and required for progestin-induced proliferation in a
pathway that does not bind PR to Cdc2 proximal promoter.
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Figure S1 Estradiol effects on validated Transcription
Factors and Cell Cycle Regulators. UIII cells were treated as
described in Figure 1B and treated with vehicle (OH), R5020
10210 M (R10) or Estradiol 1028 M (E8) for 45 minutes in a
serum-free culture medium. Graphs show JunD, Usf1, Cyr61,
Cdkn1b mRNAs expression determined by q-PCR. Gfi1, Ccnd1 and
c-Myc mRNAs expression was analyzed by sq-PCR and represen-
tative electrophoresis gels stained with sybr-green are shown in the
insets. In all cases values for gene fold change relative to b-Actin
were divided by the vehicle-treated value. Data represent average
6 SEM from 3–5 independent experiments. *P,0.05, **P,0.01,
***P,0.001.
(TIF)
Figure S2 Progestin regulation of Crebbp transcription
factor targets. UIII cells were treated as indicated in Fig. 1D.
The values for mRNAs fold change relative to b-Actin were divided
by the vehicle-treated value for each time point tested. A) Crebbp,
CcnE and b-Actin at 45 minutes, 2, 6, 12 and 24 h of 10210 M
R5020. Data represent average 6 SEM from 3 to 5 independent
experiments. **P,0.01 vs vehicle. B) representative products of
sq-PCR of these genes in 30 minutes RU486 pre-treated cells from
three independent experiments with similar results.
(TIF)
Table S1 PCR primer sequences designed by OLIGO
Primer Analysis Software (Molecular Biology Insights,
Inc.).
(DOC)
Table S2 PCR primers position relative to Cdc2 Tran-
scription Start Site (TSS). Primers Ubs 1 and 3 correspond to
region 1 and 3 respectively, while primers nUbs 2 and 4
correspond to regions 2 and 4 respectively in figure 5C. Primers
Ubs 1 bis are located just upstream of the Ubs 1 pair and cover a
region which partially overlaps with region 1, namely 1 bis.
(DOC)
Table S3 Progestin-dependent up-regulated gene ex-
pression pattern. The table shows individual fold changes of
up-regulated genes after 45 min treatment with R5020 10210 M
related to vehicle. Data were taken from three independent
samples (E1, E2, E3) and one dye swap experiment (1DS) analyzed
by microarray and expressed by mean fold change of all 4 values
(FC). Colour scale for up (red), non (black) and down (green)
regulated genes is shown.
(DOC)
Table S4 Progestin-dependent down-regulated gene
expression pattern. The table shows individual fold changes
of statistical down-regulated genes after 45 min treatment with
R5020 10210 M related to vehicle. Down (green) regulated genes
are ordered by increasing mean fold change. Data shown as
indicated in Table S3.
(DOC)
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